Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study.

JCO oncology advances·2026
Same author

An international framework for clinical translation of molecular classifiers in osteosarcoma.

NPJ precision oncology·2026
Same author

Sociodemographics and Attrition in Children With Osteosarcoma Enrolled in the AOST0331 Clinical Trial.

JAMA network open·2026
Same author

Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody-Drug Conjugate in Preclinical Osteosarcoma Models.

Molecular cancer therapeutics·2026
Same author

A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children's Oncology Group.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

A pan-cancer analysis revealed <i>SKP2</i> as an inhibitor of the tumor immune microenvironment and a promising therapeutic target for immunotherapy.

Precision clinical medicine·2025
Same journal

Molluscum Contagiosum Treatments in Children: A Systematic Review with Network Meta-Analysis.

Paediatric drugs·2026
Same journal

Real-World Systemic Treatment Patterns and Outcomes of Children With Severe Alopecia Areata: A French Nationwide Study (ESTAPED ohort).

Paediatric drugs·2026
Same journal

Epinephrine Underuse for Anaphylaxis in Infants and Toddlers: A Practical Review for Pediatricians.

Paediatric drugs·2026
Same journal

Risks of Undertreatment and Overtreatment in Pediatric Inflammatory Bowel Disease: Navigating the Balance.

Paediatric drugs·2026
Same journal

Discontinuing Colchicine in Pediatric Familial Mediterranean Fever: Real-Life Experience from a Long-Term Follow-Up Cohort.

Paediatric drugs·2026
Same journal

Sirolimus Therapy and Dyslipidemia in Neonates and Infants: A Retrospective Cohort and Pharmacovigilance Analysis.

Paediatric drugs·2026
See all related articles

Related Experiment Video

Updated: Jul 2, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Therapy for osteosarcoma: where do we go from here?

Alexander J Chou1, David S Geller, Richard Gorlick

  • 1Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, USA.

Paediatric Drugs
|August 30, 2008
PubMed
Summary
This summary is machine-generated.

This study evaluates adding ifosfamide and etoposide or pegylated interferon-alpha-2b to standard chemotherapy for osteosarcoma, aiming to improve survival rates for children and adolescents with this bone cancer.

More Related Videos

Gavage Strategy for Decoction Formula of Traditional Chinese Medicine in Osteosarcoma Model Mice
03:11

Gavage Strategy for Decoction Formula of Traditional Chinese Medicine in Osteosarcoma Model Mice

Published on: June 7, 2024

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Related Experiment Videos

Last Updated: Jul 2, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Gavage Strategy for Decoction Formula of Traditional Chinese Medicine in Osteosarcoma Model Mice
03:11

Gavage Strategy for Decoction Formula of Traditional Chinese Medicine in Osteosarcoma Model Mice

Published on: June 7, 2024

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Area of Science:

  • Pediatric Oncology
  • Skeletal System Neoplasms
  • Medical Oncology

Background:

  • Osteosarcoma is the most common primary bone malignancy in children and adolescents.
  • Current treatment combines multi-agent chemotherapy with surgical resection.
  • Existing protocols utilize cisplatin, doxorubicin, and methotrexate.

Purpose of the Study:

  • To determine if adding ifosfamide and etoposide improves survival in poor-response osteosarcoma.
  • To assess if pegylated interferon-alpha-2b maintenance improves survival in good-response osteosarcoma.
  • To explore novel strategies for relapsed or metastatic osteosarcoma.

Main Methods:

  • A national and international cooperative trial for newly diagnosed osteosarcoma.
  • Evaluation of event-free and overall survival.
  • Analysis of histologic response to neoadjuvant chemotherapy.

Main Results:

  • Survival rates for localized osteosarcoma are over 70%, but <20% for metastatic or recurrent disease.
  • Treatment outcomes for relapsed or metastatic osteosarcoma remain challenging.
  • Few improvements in survival statistics over the past two decades.

Conclusions:

  • Optimizing chemotherapy regimens and maintenance therapy is crucial for improving osteosarcoma patient outcomes.
  • Emerging strategies focus on overcoming chemotherapy resistance and targeting the tumor microenvironment.
  • Novel therapeutic approaches are needed to enhance survival for patients with advanced osteosarcoma.